
By Biomed Group: Amicus Therapeutics ( FOLD ) is a biopharmaceutical company ..... with lysosomal storage diseases. Amicus ' lead programs include the small ..... combination with ERT for Pompe disease. Amicus and its partner GlaxoSmithKline
Amicus Therapeutics , Inc. ( FOLD ) Q1 2013 Results Earnings Call ..... gentlemen. And welcome to the Amicus Therapeutics First Quarter 2013 Results Conference ..... seekingalpha.com/article/1422841- amicus -ceo-discusses-q1-2013
Amicus Therapeutics , Inc. ( FOLD ) Q42012 Earnings Call March ..... gentlemen. And welcome to the Amicus Therapeutics full year 2012 results conference ..... com/article/1268891- amicus - therapeutics -ceo-discusses-q4-2012
Amicus Theraputics ( FOLD ): Q4 EPS of -$0.20 beats by $0.17 . Shares -1.6% AH. ( PR ) Post your comment!
for every rule there is an exception, and I think Amicus Therapeutics ( FOLD ) may just be that rare exception. While I realize ..... to theology than biotechnology, I do believe that Amicus 's lead drug is effective and safe, and I hope
the devil is in the detail. Amicus Therapeutics ' ( FOLD ) attempts to add more detail ..... the tide of sentiment, leaving Amicus with only the hope of some improvement ..... at first you don’t succeed Amicus , however, should be admired
Amicus Therapeutics , Inc. ( FOLD ) Lysosomal Disease Network ..... gentlemen and welcome to the Amicus Therapeutics Lysosomal Disease Network WORLD ..... com/article/1189151- amicus - therapeutics -ceo-presents-lysosomal
Amicus Therapeutics ( FOLD -24.7% ) tanks after reporting additional Stage 1 results from the ongoing Phase 3 study of oral migalastat HCl monotherapy
A Brief Overview Of Amicu s And Fabry Disease The last time I took a look at the orphan drug specialist Amicus Therapeutics (NASDAQ: FOLD ) , we were all waiting on the phase III results for their flagship drug Migalastat HCL (which was Complete
By Ed's Stock Engineering: Amicus Theraputics ( FOLD ) is a biopharmaceutical company focused ..... later. The Story Begins In July '12 Amicus popped up on my radar screen in July ..... GSK ) expanding its partnership with Amicus for drug development. GSK has a headquarters